These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22751729)

  • 1. A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.
    Yoo BH; Axlund SD; Kabos P; Reid BG; Schaack J; Sartorius CA; LaBarbera DV
    J Biomol Screen; 2012 Oct; 17(9):1211-20. PubMed ID: 22751729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties.
    Axlund SD; Yoo BH; Rosen RB; Schaack J; Kabos P; Labarbera DV; Sartorius CA
    Horm Cancer; 2013 Feb; 4(1):36-49. PubMed ID: 23184698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers.
    Kabos P; Haughian JM; Wang X; Dye WW; Finlayson C; Elias A; Horwitz KB; Sartorius CA
    Breast Cancer Res Treat; 2011 Jul; 128(1):45-55. PubMed ID: 20665103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a.
    Finlay-Schultz J; Cittelly DM; Hendricks P; Patel P; Kabos P; Jacobsen BM; Richer JK; Sartorius CA
    Oncogene; 2015 Jul; 34(28):3676-87. PubMed ID: 25241899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells.
    Ogba N; Manning NG; Bliesner BS; Ambler SK; Haughian JM; Pinto MP; Jedlicka P; Joensuu K; Heikkilä P; Horwitz KB
    Breast Cancer Res; 2014 Dec; 16(6):489. PubMed ID: 25475897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells.
    Fettig LM; McGinn O; Finlay-Schultz J; LaBarbera DV; Nordeen SK; Sartorius CA
    Oncogene; 2017 Nov; 36(44):6074-6084. PubMed ID: 28692043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease.
    Knox AJ; Scaling AL; Pinto MP; Bliesner BS; Haughian JM; Abdel-Hafiz HA; Horwitz KB
    Breast Cancer Res; 2014 Aug; 16(4):418. PubMed ID: 25116921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts.
    Horwitz KB; Dye WW; Harrell JC; Kabos P; Sartorius CA
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5774-9. PubMed ID: 18391223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4.
    Cittelly DM; Finlay-Schultz J; Howe EN; Spoelstra NS; Axlund SD; Hendricks P; Jacobsen BM; Sartorius CA; Richer JK
    Oncogene; 2013 May; 32(20):2555-64. PubMed ID: 22751119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokeratin 5 alters β-catenin dynamics in breast cancer cells.
    McGinn O; Ward AV; Fettig LM; Riley D; Ivie J; Paul KV; Kabos P; Finlay-Schultz J; Sartorius CA
    Oncogene; 2020 Mar; 39(12):2478-2492. PubMed ID: 31988452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch.
    Haughian JM; Pinto MP; Harrell JC; Bliesner BS; Joensuu KM; Dye WW; Sartorius CA; Tan AC; Heikkilä P; Perou CM; Horwitz KB
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2742-7. PubMed ID: 21969591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttranslationally modified progesterone receptors direct ligand-specific expression of breast cancer stem cell-associated gene programs.
    Knutson TP; Truong TH; Ma S; Brady NJ; Sullivan ME; Raj G; Schwertfeger KL; Lange CA
    J Hematol Oncol; 2017 Apr; 10(1):89. PubMed ID: 28412963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
    Singhal H; Greene ME; Tarulli G; Zarnke AL; Bourgo RJ; Laine M; Chang YF; Ma S; Dembo AG; Raj GV; Hickey TE; Tilley WD; Greene GL
    Sci Adv; 2016 Jun; 2(6):e1501924. PubMed ID: 27386569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.
    Sato T; Tran TH; Peck AR; Girondo MA; Liu C; Goodman CR; Neilson LM; Freydin B; Chervoneva I; Hyslop T; Kovatich AJ; Hooke JA; Shriver CD; Fuchs SY; Rui H
    Oncogene; 2014 Apr; 33(17):2215-24. PubMed ID: 23708665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
    Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
    Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells.
    Diep CH; Charles NJ; Gilks CB; Kalloger SE; Argenta PA; Lange CA
    Cell Cycle; 2013 May; 12(9):1433-49. PubMed ID: 23574718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.
    Liu R; Zhou Z; Zhao D; Chen C
    Mol Endocrinol; 2011 Jul; 25(7):1137-44. PubMed ID: 21566082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone receptor-negative human breast cell tumors.
    Wiebe JP; Zhang G; Welch I; Cadieux-Pitre HA
    Breast Cancer Res; 2013 May; 15(3):R38. PubMed ID: 25927181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.